Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 14, 2023

SELL
$6.56 - $10.95 $32,800 - $54,750
-5,000 Reduced 6.85%
68,014 $465,000
Q2 2023

Aug 14, 2023

BUY
$7.89 - $10.64 $576,080 - $776,868
73,014 New
73,014 $757 Million
Q1 2023

May 15, 2023

SELL
$7.07 - $17.95 $360,676 - $915,719
-51,015 Reduced 37.88%
83,678 $676,000
Q4 2022

Feb 14, 2023

BUY
$14.33 - $18.37 $304,756 - $390,674
21,267 Added 18.75%
134,693 $0
Q2 2022

Aug 12, 2022

BUY
$10.16 - $17.08 $608,827 - $1.02 Million
59,924 Added 112.0%
113,426 $1.58 Million
Q1 2022

May 16, 2022

BUY
$9.74 - $17.92 $521,109 - $958,755
53,502 New
53,502 $922,000

Others Institutions Holding ACRS

About Aclaris Therapeutics, Inc.


  • Ticker ACRS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 66,671,800
  • Market Cap $253M
  • Description
  • Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments: Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant ...
More about ACRS
Track This Portfolio

Track Ubs Oconnor LLC Portfolio

Follow Ubs Oconnor LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Oconnor LLC, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Oconnor LLC with notifications on news.